Novartis AG Earnings: Everything You Must Know Now

Novartis AG (NYSE:NVS) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

Novartis AG Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased 5.8% to $1.3 in the quarter versus EPS of $1.38 in the year-earlier quarter.

Revenue: Decreased 0.36% to $14.49 billion from the year-earlier quarter.

Actual vs. Wall St. Expectations: Novartis AG reported adjusted EPS income of $1.3 per share. By that measure, the company beat the mean analyst estimate of $1.29. It beat the average revenue estimate of $14.39 billion.

Quoting Management: “With a pipeline of more than 25 new molecular entities, we are at the forefront of a new era in oncology drug development, working towards advances for cancer patients,” said Herve Hoppenot, President, Novartis Oncology. “These data demonstrate our progress in furthering research and development through a highly-targeted approach, matching specific compounds to pathways that are involved in many difficult-to-treat cancers.”

Key Stats (on next page)…

Revenue increased 1.99% from $14.21 billion in the previous quarter. EPS decreased 1.52% from $1.32 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $1.31 to a profit $1.29. For the current year, the average estimate has moved up from a profit of $5.09 to a profit of $5.11 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]